Laminin-α2 Chain-Deficient Congenital Muscular Dystrophy
- 1 January 2015
- book chapter
- Published by Elsevier
- Vol. 76, 31-60
Abstract
No abstract availableKeywords
This publication has 133 references indexed in Scilit:
- Laminin-111 Protein Therapy Reduces Muscle Pathology and Improves Viability of a Mouse Model of Merosin-Deficient Congenital Muscular DystrophyThe American Journal of Pathology, 2012
- Apoptosis inhibitors and mini‐agrin have additive benefits in congenital muscular dystrophy miceEMBO Molecular Medicine, 2011
- A Dystroglycan Mutation Associated with Limb-Girdle Muscular DystrophyNew England Journal of Medicine, 2011
- Autophagy in skeletal muscleFEBS Letters, 2010
- Basal lamina strengthens cell membrane integrity via the laminin G domain-binding motif of α-dystroglycanProceedings of the National Academy of Sciences, 2009
- Pathology is alleviated by doxycycline in a laminin‐α2–null model of congenital muscular dystrophyAnnals of Neurology, 2009
- Cib2 Binds Integrin α7Bβ1D and Is Reduced in Laminin α2 Chain-deficient Muscular DystrophyJournal of Biological Chemistry, 2008
- Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophyNature Medicine, 2008
- An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophyNature, 2001
- Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrixNature, 1992